Welcome to our dedicated page for Prestige Consumer Healthcare news (Ticker: PBH), a resource for investors and traders seeking the latest updates and insights on Prestige Consumer Healthcare stock.
Prestige Consumer Healthcare Inc. (NYSE: PBH) is a leading provider of over-the-counter (OTC) healthcare products, serving consumers across North America and globally in markets such as Australia, New Zealand, and Asia. The company boasts a diverse portfolio of trusted brands that include household names like Clear Eyes, DenTek, Summer's Eve, Monistat, BC, Goody's, and Dramamine, among others. With a focus on product innovation and quality, Prestige Consumer Healthcare aims to enhance the lives of its customers worldwide.
Founded on the principles of trust and reliability, Prestige Consumer Healthcare is recognized as the largest independent provider of OTC healthcare products in North America. The company's success is attributed to its ability to remain agile while maintaining detailed attention to its extensive range of product offerings. This is reflected in the company's consistent efforts to improve and create products that align with the ever-evolving needs of consumers and their families.
Recent achievements for Prestige Consumer Healthcare include strong financial performances, as evidenced by their second quarter fiscal 2024 results. The company reported revenues of $286.3 million and a net income of $53.6 million, highlighting a robust growth in earnings per share. This was driven by the diverse and leading portfolio of brands, along with broad distribution and a solid financial model. Strong performances in categories such as Cough & Cold and Ear & Eye Care contributed significantly to these results.
In terms of financial health, Prestige Consumer Healthcare continues to demonstrate strong cash flow generation. For the second quarter of fiscal 2024, the company reported net cash provided by operating activities at $62.5 million and a non-GAAP free cash flow of $59.5 million. Debt reduction and disciplined capital deployment remain key priorities, with the company reducing its net debt to approximately $1.2 billion and achieving a leverage ratio of 3.0x.
Partnerships and global reach are also integral to Prestige Consumer Healthcare's strategy. The company generates around 85% of its total revenue from North America, with the remaining sales coming from international markets. Key brands such as Hydralyte in Australia and niche consumer health products in other regions underscore the company's global presence and commitment to meeting diverse healthcare needs.
Looking ahead, Prestige Consumer Healthcare is optimistic about its growth prospects, reaffirming its fiscal 2024 outlook with expectations of continued sales and earnings growth. The company remains well-positioned to create long-term shareholder value through stable organic growth and strategic capital allocation.
Prestige Consumer Healthcare (NYSE:PBH) has announced two important upcoming events. First, the company will release its fiscal 2025 third quarter earnings on Thursday, February 6, 2025, before market opening, followed by a conference call at 8:30 a.m. ET. Investors can join the webcast through the company's Investor Relations webpage or register for phone participation.
Additionally, PBH will participate in a fireside chat at the 27th annual ICR Conference in Orlando, FL on Tuesday, January 14th, at 11:30 a.m. ET. Both events will be accessible via webcast on the company's website, with replays available afterward.
Prestige Consumer Healthcare (NYSE: PBH) has expanded the role of Chief Financial Officer Christine Sacco to include Chief Operating Officer responsibilities, effective immediately. In this enhanced role, Ms. Sacco will oversee the Company's supply chain along with her existing CFO duties. She will continue to report to CEO Ron Lombardi. Lombardi highlighted Sacco's strategic leadership and deep understanding of the business, which have been instrumental in the company's growth over her 8-year tenure as CFO.
Ms. Sacco, a seasoned executive with over 27 years of experience in the consumer products and specialty pharma sectors, has been the CFO since 2016. Her tenure has seen significant contributions to Prestige's strategic transformation and financial success, including strong sales, earnings, and cash flow growth. This expanded role aims to enhance the execution of strategic initiatives and drive operational excellence, positioning Prestige for further organic and M&A growth.
Prestige Consumer Healthcare reported Q2 fiscal 2025 results with revenue of $283.8 million, down 0.9% year-over-year. Diluted EPS increased 2% to $1.09. Net cash from operations grew 13% to $125 million in first six months. The company reduced debt by $75 million and repurchased $38 million in shares year-to-date.
Q2 performance was driven by strong growth in International and Canadian businesses, offsetting Clear Eyes® supply constraints. The company reaffirmed its fiscal 2025 outlook with revenue guidance of $1,125-$1,140 million, organic revenue growth of approximately 1%, and adjusted EPS of $4.40-$4.46.
Prestige Consumer Healthcare Inc. (NYSE:PBH) has announced the release date for its fiscal 2025 second quarter earnings. The company will issue the earnings release on Thursday, November 7, 2024, before the market opens. Following the release, Prestige Consumer Healthcare will host a conference call at 8:30 a.m. ET to discuss the results.
Investors and interested parties can participate in the earnings discussion through two methods:
- A live Internet webcast accessible from the Investor Relations page of www.prestigeconsumerhealthcare.com
- A conference call via phone, with registration required to receive dial-in details and a unique pin
Participants are advised to join 10 minutes prior to the event start. A replay of the conference call will be available for approximately one week on the company's Investor Relations page.
Prestige Consumer Healthcare (NYSE:PBH) has announced its participation in the Barclays Global Consumer Staples Conference on Thursday, September 5, 2024, at 2:15 p.m. ET. The company will present at this significant industry event, offering insights into its operations and strategy.
Interested parties can access a live webcast of the presentation through the company's official website under the 'Investors' section and 'Events and Presentations' tab. For those unable to attend the live event, a replay option will be available on the company's website following the presentation. This announcement highlights Prestige Consumer Healthcare's commitment to investor relations and transparency in its business operations.
Prestige Consumer Healthcare Inc. (NYSE:PBH) reported Q1 fiscal 2025 results with revenue of $267.1 million, down 4.4% year-over-year but ahead of expectations. EPS was $0.98 and adjusted EPS was $0.90, compared to $1.06 in the prior year. Cash from operations increased 13.9% to $54.8 million. The company reduced debt by $35 million and repurchased $26 million in shares.
Key highlights:
- North American OTC Healthcare segment revenue decreased 5.6% to $232.3 million
- International OTC Healthcare segment revenue increased 5.0% to $34.8 million
- Free cash flow increased to $53.6 million
- Net debt position of approximately $1.1 billion with a leverage ratio of 2.8x
The company reaffirmed its full-year fiscal 2025 outlook, expecting revenue of $1,125 to $1,140 million, organic revenue growth of approximately 1%, and adjusted EPS of $4.40 to $4.46.
Prestige Consumer Healthcare announced its fiscal 2025 first quarter earnings release will be issued on August 8, 2024, before the market opens.
The company will host a conference call to discuss the results at 8:30 a.m. ET the same day. Participants can join the live Internet webcast via the Investor Relations page on the company's website. Phone participants need to register to receive dial-in details and a unique pin. It is recommended to join the call 10 minutes early. A replay of the conference call will be available for a week on the Investor Relations page.
Prestige Consumer Healthcare (NYSE:PBH) will present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference on June 10, 2024, at 1:30 p.m. ET. Interested parties can access a live webcast of the event via the company's website under the 'Investors' section or use the provided link. A replay will be available for those unable to attend the live session.
Prestige Consumer Healthcare (NYSE: PBH) reported its fiscal year 2024 results with $277.0 million in Q4 revenue and $1,125.4 million for the full year, a slight 0.2% increase from the previous year. Q4 net income was $49.5 million, a significant improvement from the previous year's net loss of $240.6 million. The company's leverage ratio was reduced to 2.8x, below its long-term target. The Board authorized a new $300 million share repurchase program. For fiscal 2025, Prestige anticipates a 1% organic revenue growth and an EPS range of $4.40 to $4.46. Ongoing supply chain issues, particularly in eye care products, affected Q4 performance but are expected to improve mid-2025.
FAQ
What is the current stock price of Prestige Consumer Healthcare (PBH)?
What is the market cap of Prestige Consumer Healthcare (PBH)?
What does Prestige Consumer Healthcare Inc. do?
Where does Prestige Consumer Healthcare generate most of its revenue?
What recent financial results has Prestige Consumer Healthcare reported?
How is Prestige Consumer Healthcare managing its debt?
What are some of the key brands under Prestige Consumer Healthcare?
What is the company's approach to product innovation?
What is the company's outlook for the future?
How does Prestige Consumer Healthcare support its global operations?
What is the company's financial strategy?
How can investors access the company's financial updates?
